Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $27.28 Analyst target: $95.32 Upside: 249.41%
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing new therapies for metabolic and endocrine disorders. The company is headquartered in San Diego, California.
See the full interactive analysis & chart →Informational only — not investment advice.